Randall B Sunberg

Practice Areas

Randall Sunberg is a partner in the Transactions Practice Group and the Life Sciences Industry Group. He serves as Chair of the North America Healthcare & Life Sciences Group. Randy structures and negotiates complex collaborations, mergers and acquisitions, divestitures, joint ventures, and corporate partnering and licensing transactions, as well as equity investments and royalty monetization transactions for clients ranging from biotech startups to multinational pharmaceutical companies.

In addition to pharma, biotech, medical device, diagnostics, and technology companies, Randy advises private equity, venture capital, and investment banking firms. Randy counsels on alternative financing arrangements such as royalty monetizations. He also handles technical contractual arrangements for drug discovery, development, manufacturing and supply, marketing and co-promotion, and outsourcing in the life sciences industry.

Additionally, he advises boards of directors and significant shareholders on disclosure issues, corporate communications policies, and fiduciary duty matters. He serves clients throughout Europe and Asia, and across the United States.

Randy's wealth of global life sciences experience draws many invitations to speak at industry events worldwide. He has spoken on such topics as mergers and acquisitions, strategic alliances, and licensing and collaboration transactions in the United States at Allicense, BIO and LES annual meetings; in Canada at BIOMedex; and in China at BIO Forum; as well as at other life sciences–related conferences. He has also been a guest lecturer at the Rutgers Business School MBA Biotechnology Commercialization Concentration.

Professional Memberships

American Bar Association - Member, Business Law Section

Publications

Executive Council & the New York Venture Capital Association Health & Technology Summit 2018

JPMorgan’s 34th Annual Healthcare Conference in San Francisco

Allicense 2010: Redefining the Threshold of Innovation Conference

Work Highlights

GSK in its license agreement with WuXi Biologics for multiple novel bi- and multi-specific T cell engagers.

Minoryx Therapeutics in its licensing transaction with Neuraxpharm for European rights to its PPAR gamma agonist lead candidate leriglitazone.

CSL Seqirus in its collaboration and license agreement with Arcturus Therapeutics to access its late stage self-amplifying mRNA vaccine platform technology, including for COVID-19, influenza, and multi-pathogen pandemic preparedness.

Sanifit Therapeutics in its acquisition by Vifor Pharma, including the continued development and commercialization of Sanifit's novel, first-in-class inhibitor of vascular calcification for the treatment of CUA and PAD in patients with end-stage kidney disease.

Takeda in its collaboration and license agreement with Poseida Therapeutics to utilize Poseida's piggyBac, Cas-CLOVER, biodegradable DNA and RNA nanoparticle delivery technology and genetic engineering platforms for up to eight gene therapy programs, including Hemophilia A.

H. Lundbeck A/S in its collaboration with Rgenta Therapeutics to discover small molecules targeting RNA regulation and splicing of disease-causing genes.

Takeda in its strategic collaboration with KSQ Therapeutics to identify optimal T cell and NK cell gene targets screened using KSQ’s CRISPRomics technology and to develop and commercialize novel cell and non-cell immuno-oncology therapies.

H. Lundbeck A/S in the licensing to Denovo Biopharma of global rights to idalopirdine (an oral 5-HT6 antagonist) for Alzheimer's Disease, schizophrenia and other indications, subject to options for Lundbeck to re-acquire such rights with the parties sharing China rights.

NBE Therapeutics in its collaboration with Exelixis to discover and develop antibody-drug conjugates for oncology applications.

Takeda in the sale to Neuraxpharm of global rights to the prescription brand Buccolam® (indicated for the emergency treatment of epileptic children with prolonged acute convulsive seizures).